Drug makers must now label allergen and gluten ingredients
H.R. 3821 — ADINA Act · Filed by Kelly Morrison (D-MN) · 21 cosponsors · Introduced Jun 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires drug manufacturers to clearly label any ingredient in human medications that is or comes from a major food allergen (peanuts, tree nuts, milk, eggs, fish, shellfish, soy, sesame) or gluten-containing grains (wheat, barley, rye). If a drug contains such an ingredient and the label does not identify it, the drug is considered misbranded under federal law. Manufacturers have up to 2 years to comply.
Why we flagged it
The bill's sole operative mechanism is a labeling requirement for drug manufacturers. It adds a new misbranding standard under the FDCA, requiring disclosure of allergen and gluten-grain ingredients on human drug labels.
What the text implies
- Applies to all human drugs (prescription, OTC, biologics) — scope is broad and includes compounded medications if they fall under FDCA jurisdiction.
- Misbranding violation triggers FDA enforcement authority including seizure, injunction, and criminal penalties — non-compliance carries significant regulatory teeth.
- Does not specify label format, font size, or placement — FDA will issue guidance, creating potential for variation in how allergen information is presented.
- Applies to indirect derivation (e.g., a drug ingredient derived from a plant that is a major allergen) — scope is wider than direct allergen presence alone.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
People with food allergies and celiac disease gain critical safety information needed to avoid potentially life-threatening drug exposures. The requirement imposes a labeling cost on manufacturers but creates no new restrictions on citizens' access to medications—only transparency about what is in them.
Named in the bill
FDA (Food and Drug Administration), HHS (Department of Health and Human Services), FDCA (Federal Food, Drug, and Cosmetic Act), Section 502 (misbranding provision)
Where it stands
21 cosponsors: 13 Democrats, 8 Republicans.
- Jun 6, 2025 — Introduced · Congress.gov: “Introduced in House”
- Jun 6, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,081 characters) on Sep 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 14,522 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-09-21.
“Drug makers must now label allergen and gluten ingredients” QuorumCivic. https://share.quorumcivic.app/bill/119/hr3821 Report an error